These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 29895211)

  • 1. A case of a patient with severe renal failure on hemodialysis treated with vismodegib for relapsing basal cell carcinoma.
    Sbrana A; Antonuzzo A; Galli L; Biasco E; Musettini G; Paolieri F; Ricci S
    Tumori; 2018 Dec; 104(6):NP2-NP4. PubMed ID: 29895211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
    Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
    J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma.
    Pollom EL; Bui TT; Chang AL; Colevas AD; Hara WY
    JAMA Dermatol; 2015 Sep; 151(9):998-1001. PubMed ID: 25874733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inoperable infiltrative basal cell carcinoma successfully treated with vismodegib.
    Zargari O; Azimi SZ; Geranmayeh S
    Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28631369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
    Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
    Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
    Sekulic A; Migden MR; Lewis K; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Dirix L; Hou J; Yue H; Hauschild A;
    J Am Acad Dermatol; 2015 Jun; 72(6):1021-6.e8. PubMed ID: 25981002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice.
    Calzavara Pinton P; Licitra L; Peris K; Santoro A; Ascierto PA
    Future Oncol; 2015; 11(9):1429-35. PubMed ID: 25952787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry.
    Sekulic A; Yoo S; Kudchadkar R; Guillen J; Rogers G; Chang ALS; Guenthner S; Raskin B; Dawson K; Mun Y; Chu L; McKenna E; Lacouture M
    PLoS One; 2022; 17(1):e0262151. PubMed ID: 35030185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary Resistance to Vismodegib After Initial Successful Treatment of Extensive Recurrent Periocular Basal Cell Carcinoma with Orbital Invasion.
    Papastefanou VP; René C
    Ophthalmic Plast Reconstr Surg; 2017; 33(3S Suppl 1):S68-S70. PubMed ID: 26398246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Food and Drug Administration Approval of Vismodegib on Prevalence of Orbital Exenteration as a Necessary Surgical Treatment for Locally Advanced Periocular Basal Cell Carcinoma.
    Sagiv O; Ding S; Ferrarotto R; Glisson B; Altan M; Johnson F; Elamin Y; Thakar SD; Nagarajan P; Esmaeli B
    Ophthalmic Plast Reconstr Surg; 2019; 35(4):350-353. PubMed ID: 30365473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma.
    Mathis J; Doerr T; Lin E; Ibrahim SF
    Dermatol Surg; 2019 Jan; 45(1):17-25. PubMed ID: 30586344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Vismodegib in the Management of Advanced Periocular Basal Cell Carcinoma.
    Cox KF; Margo CE
    Cancer Control; 2016 Apr; 23(2):133-9. PubMed ID: 27218790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma.
    Axelson M; Liu K; Jiang X; He K; Wang J; Zhao H; Kufrin D; Palmby T; Dong Z; Russell AM; Miksinski S; Keegan P; Pazdur R
    Clin Cancer Res; 2013 May; 19(9):2289-93. PubMed ID: 23515405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete response is reversible upon vismodegib withdrawal and re-inducible upon vismodegib rechallenge in a patient with locally advanced basal cell carcinoma.
    Dessinioti C; Plaka M; Dimitrakopoulou A; Stratigos AJ
    J Eur Acad Dermatol Venereol; 2019 May; 33(5):e187-e188. PubMed ID: 30653740
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.
    Chang AL; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
    Orphanet J Rare Dis; 2016 Sep; 11(1):120. PubMed ID: 27581207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive Basal Cell Carcinoma of the Skin Treated Successfully with Vismodegib: A Case Report.
    Awad R; Andrade JCB; Mousa H; Mahmoud F
    Perm J; 2018; 22():17-181. PubMed ID: 30005721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vismodegib: in locally advanced or metastatic basal cell carcinoma.
    Keating GM
    Drugs; 2012 Jul; 72(11):1535-41. PubMed ID: 22788238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience With Vismodegib in the Treatment of Advanced Basal Cell Carcinoma at a Cancer Center.
    Bernia E; Llombart B; Serra-Guillén C; Bancalari B; Nagore E; Requena C; Calomarde L; Diago A; Lavernia J; Traves V; Guillén C; Sanmartín O
    Actas Dermosifiliogr (Engl Ed); 2018 Nov; 109(9):813-820. PubMed ID: 30055751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus.
    Peris K; Licitra L; Ascierto PA; Corvò R; Simonacci M; Picciotto F; Gualdi G; Pellacani G; Santoro A
    Future Oncol; 2015; 11(4):703-12. PubMed ID: 25686123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.